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Autocrine secretion of transforming growth factor-f3 in cultured
rat mesangial cells
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Autocrine secretion of transforming growth factor-a in cultured rat
mesangial cells. Transforming growth factor-p (TGF-p) recently has
been shown to modulate mesangial cell growth and to stimulate
mesangial matrix synthesis by mesangial cells. Here we examined
whether mesangial cells expressed TGF-p mRNA and secreted mature
TGF-/3, and we investigated the role of TGF-/3 in mesangial cell growth.
Cultured rat mesangial cells expressed 2.5 kb TGF-f3 mRNA, and
removal of fetal calf serum (FCS) for two days decreased the TGF-f3
mRNA level, which was then stimulated by re-addition of 17% FCS
reaching the maximum at nine hours. 12-0-tetradecanoyl phorbol-l3-
acetate (TPA), one of the phorbol esters, markedly increased the
mRNA level and reached the maximum at six or nine hours. Immuno-
blot analysis of the conditioned media using specific anti-TGF-f31
antibodies revealed single 12.5 kDa proteins, the size compatible with
mature TGF-P subunits. By means of bioassay using CCL-64 cell line,
TGF-p production rate by mesangial cells was estimated to be 22.1
6.5 (mean so) ng/l06 cells/24 hours, 96% of which was in latent forms.
Exogenously added TGF-p inhibited mesangial cell growth at 10 M or
higher. Moreover, addition of anti-TGF-f3 neutralizing antibodies aug-
mented mesangial cell growth, indicating that the secreted TGF-p
actually exerted a growth-inhibitory action. In summary, mesangial
cells produce and secrete substantial amounts of TGF-p but mostly in
latent forms, and the secreted TGF-/3 may regulate mesangial cell
growth and differentiation. We conclude that TGF-/3 may function as an
autocrine factor in mesangial cells.
Transforming growth factor-p (TGF-/3) is a disulfide-linked
homodimer of 25 kilodalton (kDa) polypeptide [I, 2]. TGF-13 is
synthesized as an inactive precursor protein which may bind to
a 120 to 130 kDa TGF-/3 binding protein, and is proteolytically
processed into an active mature form [3]. Since its first purifi-
cation from human platelets [4], TGF-/3 has been shown to be a
multifunctional regulator of cell proliferation and differentiation
[1, 2, 5—7]. Inhibition of cell proliferation is generally seen in
many cells, in particular, epithelial cells, whereas some mesen-
chymal cells may be stimulated to proliferate by TGF-p [1, 5,
6]. In addition, TGF-/3 has been shown to contribute to the
accumulation of extracellular matrix proteins by stimulating
their synthesis and/or decreasing the activities of some extra-
cellular proteases [7, 8].
The kidney is one of the targets of TGF-/3 action. The
Received for publication April 16, 1992
and in revised form July 28, 1992
Accepted for publication July 29, 1992
© 1992 by the International Society of Nephrology
presence of specific receptors for TGF-/3 has been demon-
strated in both isolated glomeruli and in the individual cell types
of the glomerulus, that is, mesangial, epithelial and endothelial
cells [91. TGF-/3 has been shown to inhibit mesangial cell
growth [9, 10] and to stimulate the synthesis of collagen,
fibronectin, laminin, and other proteoglycans such as heparan
sulfate by mesangial cells as well as glomerular epithelial cells
[9, 11].
TGF-p is richest in platelets [4] but is found in almost all
normal and transformed cells. Recently isolated glomeruli have
been shown to express TGF-p mRNA and produce TGF-13
proteins [12—14]. Furthermore, Okuda et al have recently dem-
onstrated in a rat model of experimental glomerulonephritis that
TGF-/3 mRNA expression and its production in the glomeruli
are augmented in parallel to the mesangial matrix accumulation
[14], which is prevented by injecting anti-TGF-f3 neutralizing
antibodies [15]. Based on these observations they have sug-
gested that TGF-p may play a crucial role in the pathogenesis of
glomerulonephritis, although it is not known what cell types in
the glomerulus are responsible for the TGF-/3 production and
what is the mechanism by which the TGF-p secretion is
stimulated.
Recently mesangial cells have been shown to have many
functions such as contractile properties in response to vasoac-
tive peptides, phagocytosis of macromolecules, and synthesis
of matrix proteins, eicosanoids, oxygen radicals, and several
autacoids [16]. In addition, they may produce and respond to
growth factors such as interleukin-1 [17], platelet-derived
growth factor (PDGF) [18], insulin-like growth factor-I [19],
and interleukin-6 [20]. These growth factors may play some
important roles for mesangial cell proliferation in vivo as
autocrine or paracrine factors in the physiology and pathophys-
iology affecting the kidney.
The present study was designed, therefore: (1) to elucidate
whether mesangial cells express TGF-f3 mRNA and secrete
TGF-f3 proteins, and if so, (2) to investigate whether the
secreted TGF-f3 is an active or inactive form and (3) what is the
mechanism by which the induction of TGF-f3 is regulated, and
finally (4) to examine the role of TGF-/3 in the mesangial cell
growth. The results showed that mesangial cells clearly express
TGF-p mRNA, which may be stimulated by serum and TPA,
and that mesangial cells secreted substantial amounts of TGF-13
proteins mostly in latent forms. In addition, the secreted TGF-13
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demonstrated growth-inhibitory action on mesangial cells them-
selves and thus TGF-f3 may function as an autocrine factor in
mesangial cells.
Methods
Mesangial cell culture
Mesangial cells were obtained by culturing glomeruli isolated
from kidneys of 150 to 200 g male Wistar rats by conventional
sieving methods [21, 22]. Cells which outgrew in Eagle's
minimal essential medium (MEM) containing 17% FCS were
identified to be mesangial cells by phase contrast microscopy
according to the morphological criteria, that is, flat polygonal or
spindle-shaped cells with multiple processes 122]. All experi-
ments were performed using the cells between the 4th and the
10th passages.
Preparation of conditioned media (CM) by mesangial cells
and activation of latent TGF-/3
The serum-free media conditioned by confluent mesangial
cells for 24 hours were collected, centrifuged to remove cell
debris, and subjected to bioassay and immunoblot analysis. The
activation of latent TGF-13 was performed by heating CM at
80°C for 10 minutes or by acidifying CM with one-tenth amount
of 10 N HCI (final pH 1.5 2) for 30 minutes at room
temperature, followed by neutralization with an equimolar
NaOH [23, 24].
Bioassay for TGF-f3 activities
The bioassay for TGF-/3 was performed based on the obser-
vation that TGF-p sensitively inhibits the growth of CCL-64
cells (mink lung epithelial cell line) [25]. In brief, CCL-64 cells
were plated into 24-well culture plates in MEM containing 10%
FCS. After incubation for 24 hours the medium was discarded
and changed to MEM containing 1% FCS. After additional
incubation for 24 hours control or test samples were added, and
cells were incubated for another 16 to 24 hours. Subsequently,
18 kBq/well [3H]-thymidine was pulsed for three to five hours
and the amounts of [3H]-thymidine incorporated into trichloro-
acetic acid (TCA)-precipitable materials were measured by a
liquid scintillation counter. TGF-/3 activities were determined
as compared with the standard curve which was drawn by using
human TGF-f31.
Immunoblot analysis of TGF-f3 proteins
CM were dialyzed against 1 m acetic acid for 24 hours and
lyophilized. The lyophilized products were solubilized by boil-
ing in the presence of sodium dodecyl sulfate (SDS) and
2-mercaptoethanol, size-fractionated by 5 to 10% SDS-poly-
acrylamide gel electrophoresis, and electrophoretically trans-
ferred to a polyvinylidene difluoride membrane filter (Immo-
bilon-P, Millipore, Bedford, Massachusetts, USA). The filter
was incubated in blocking buffer (150 mtvi NaCI, 20 mtvi Tris, 3%
instant nonfat dry milk, pH 7.5) for one hour to block nonspe-
cific antibody binding and treated with specific anti-TGF-/31
antibodies in Tris-NaCI buffer (150 mrvi NaC1, 20 m'vi Tris, 0.3%
instant nonfat dry milk) for three hours at room temperature.
After washing four times with Tris-NaC1 buffer and 0.05%
Tween 20, the filter was incubated in Tris-NaC1 buffer with a
diluted horseradish peroxidase-anti-rabbit IgG conjugate for
Fig. 1. Effectof FCS on TGF-f3 mRNA expression in cultured mesan-
gial cells. Total RNA was isolated from cultured mesangial cells
growing in MEM containing 17% FCS or following incubation in
serum-free MEM for 24 hours and for 48 hours. Samples (15 g total
RNA/lane) were size-fractionated in 1% agarose gel, transferred to a
nylon membrane and the Northern blot was hybridized with nick-
translated TGF-/3l and /3-actin cDNA probes.
one hour. The blot was visualized by staining the filter with
color reaction substrates (4-chloro-l-naphthol and N,
N'-dialkyl-4-aminoaniline derivatives) according to manufac-
turers instructions (Immunostaining HRP Kit IS-SOB, Konica,
Tokyo).
Northern blot analysis
Total RNA was extracted from cultured mesangial cells by a
isothiocyanate/CsCI ultracentrifugation. In some experiments
poly (A) RNA was prepared using oligo (dT)-cellulose chro-
matography (type 3, Collaborative Research, Bedford, Massa-
chusetts, USA). Aliquots (15 to 20 p.g total RNA or 2 p.g poly
(A) RNA) were size-fractionated in 2.2 M formaldehyde-1%
agarose gel and transferred to a nylon membrane by capillary
action for 12 to 18 hours. The blot was prehybridized for four to
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Fig. 2. Time course and dose-response relationship of FCS-induced TGF-/3 mRNA expression. A. Mesangial cells were serum-starved for 48
hours, and subsequently exposed to MEM containing 17% FCS. At the indicated time point following treatment with FCS, RNA was isolated from
the cells and subjected to Northern blot analysis (2 g poly (A) RNA/lane) using nick-translated TGF-/31 and /3-actin cDNA probes. B.
Serum-starved mesangial cells were incubated for six hours in MEM containing FCS at the indicated concentrations. At the end of incubation
period, total RNA was isolated from the cells and subjected to Northern blot analysis (20 jsg/lane) using nick-translated TGF-131 and /3-actin cDNA
probes.
six hours at 42°C in hybridization solution (5 X SSC, 10 X
Denhardt's solution, 0.1% SDS, and 50% formamide), and was
then hybridized with a nick-translated TGF-131 cDNA probe at
42°C in the hybridization solution for 20 to 24 hours. The filter
was washed four times with 2 x SSC, 0.1% SDS at room
temperature and once with 0.1 x SSC, 0.1% SDS at 55°C for 30
minutes. Autoradiography was performed by a standard
method. The filter was rehybridized with [32P]-labeled f3-actin
probe as an internal control after removing the radiolabeled
probe in a boiled water for 10 minutes.
[3HJ-thymidine incorporation in mesangial cells
For [3H]-thymidine incorporation study, mesangial cells were
plated on 24-well plates, grown to confluence, and growth-
arrested by incubation for 48 hours in MEM containing 0.5%
FCS. Subsequently, the medium was changed to MEM contain-
ing 10% FCS together with various concentrations of TGF-/31,
and the cells were incubated for 48 hours. The amounts of
[3H]-thymidine (37 kBq/well) incorporated into TCA-precipita-
ble materials during the last six hours of the incubation time
were measured as described above. To determine an autocrine
role of TGF-/3, we investigated the effect of anti-TGF-/3 neu-
tralizing antibodies on mesangial cell growth. After mesangial
cells became confluent, the medium was changed to serum free
MEM or MEM containing 10% FCS with or without anti-TGF-/3
neutralizing antibodies, and the cells were incubated for 48
hours. In some experiments we added 100 nM TPA to serum-
free MEM. The amounts of 13HJ-thymidine (37 kBq/well) incor-
porated into TCA-precipitable materials during the incubation
time were measured.
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Fig. 3. Effects of growth factors and TPA on TGF-/3 mRNA expres-
sion. Mesangial cells were serum-starved for 48 hours in MEM con-
taining 0.5% FCS, and incubated for six hours in serum-free MEM with
no addition, PDGF (10 ng/ml), TGF-p (10 nglml), TPA (100 nM), or in
MEM containing 17% FCS. At the end of incubation period, RNA was
isolated from the cells and subjected to Northern blot analysis (2 Lg
poly (A) RNA/lane).
Cell number analysis
To directly confirm the effect of TGF-/3 or anti-TGF-j3
neutralizing antibodies on mesangial cell proliferation, we per-
formed cell number analysis. After incubation for three or
seven days in MEM containing 10% FCS together with TGF-/31
at the indicated concentrations or anti-TGF-/3 neutralizing
antibodies (20 Lg/ml), mesangial cells were harvested with
trypsin-0.05% ethylenediaminetetraacetic acid (EDTA), and
then the cell number was counted.
Materials
TGF-/31 cDNA from rat platelets was provided by Dr.
Toshikazu Nakamura (Kyushu University Faculty of Science,
Fukuoka, Japan). About 500-base pair Bgl I/Eco RI fragment
from plasmid clone was used for Northern blot analysis. Human
platelet TGF-131 and human epidermal growth factor (EGF)
were purchased from R & D Systems (Minneapolis, Minnesota,
USA), and human PDGF from Collaborative Research Incorp.
(Bedford, Massachusetts, USA). Rabbit anti-TGF-p neutraliz-
ing antibody was obtained from R & D Systems, and polyclonal
anti-TGF-/3 antibody for immunoblot analysis was a gift of Dr.
Kohei Miyazono (Ludwig Institute for Cancer Research, Upp-
sala, Sweden). [a-32P] dCTP (ill TBq/mmol) and [3H]-thymi-
dine (185 GBq/mmol) were the products of Amersham Corp.
(Arlington Heights, Illinois, USA). Other chemicals were ob-
tained from Sigma Chemical Co. (St. Louis, Missouri, USA).
Results
TGF-13 mRNA expression in mesangial cells and
up-regulation by serum and TPA
Mesangial cells growing in MEM containing 17% FCS ex-
pressed 2.5 kb mRNA (Fig. 1), the size compatible with TGF-/3
mRNA [4]. TGF-/3 mRNA levels did not vary with cell density
(data not shown), thus mesangial cells which were grown to
confluence were used in the subsequent experiments.
To elucidate the mechanism by which TGF-13 mRNA is
expressed, we examined which factor(s) could modulate the
mRNA level in mesangial cells. Removal of FCS for two days
decreased the TGF-/3 mRNA levels, while -actin mRNA
2.5 kb remained constant (Fig. 1). The TGF-/3 mRNA level was then
stimulated by re-addition of 17% FCS reaching the maximum at
nine hours (Fig. 2A). The effect of FCS to induce TGF-/3 mRNA
levels was dose-dependent between 0.5 and 8%. The maximum
effect was achieved by addition of 8% FCS (Fig. 2B).
It has been reported in other cell types that TGF-/3 mRNA
can be induced by TPA, one of the phorbol esters [26, 27] and
by growth factors such as PDGF and epidermal growth factor
(EGF) in normal rat kidney fibroblasts, and by TGF-f3 itself in
rat osteosarcoma cells [281. Our results show that TPA also
markedly increased TGF-f3 mRNA expression in mesangial
cells (Fig. 3). Time course of the induction by TPA showed the
stimulation was seen as early as one hour and reached the
maximum at six or nine hours, which was almost the same as
the induction by FCS (Fig. 4). However, up-regulations of
TGF-/3 mRNA were not observed by addition of either PDGF,
TGF-/3, or EGF (data not shown) in mesangial cells.
Bioassay for TGF-f3 activities in the conditioned media by
mesangial cells
To examine whether cultured mesangial cells secrete biolog-
ically active TGF-p, TGF-13-like activities in the conditioned
media were measured by use of CCL-64 cell growth-inhibition
assay. As shown in Figure 5A, TGF-f3 inhibited [3H]-thymidine
incorporation in CCL-64 cells dose-dependently (ED50 = 10 to
15 pM). CM with heat or acid treatment inhibited [3H]-thymi-
dine incorporation in CCL-64 cells dose-dependently, although
CM without treatment had less effect. Anti-TGF-/3 neutralizing
antibodies completely abrogated the inhibitory effect of CM on
[3H]-thymidine incorporation in CCL-64 cells (Fig. 5 A and B),
whereas non-immune IgG had no effect (data not shown),
indicating that the inhibitory effect of CM was specific for
TGF-/3. The specificity of the anti-TGF- neutralizing antibod-
ies was confirmed by the observation that the CCL-64 cell
growth-inhibitory effect of TGF-/3 was abrogated by the anti-
bodies, but not by non-immune rabbit IgG (data not shown).
From these bioassay studies, the concentrations of TGF-f3 in
the conditioned media for 24 hours without activation were
estimated to be 10 — 20 M (14.8 3.6 pM) but markedly
increased to 150 450 M (282.5 119.3 pM) after heat or acid
activation. Based on these results, the amounts of TGF-f3
produced by mesangial cells were calculated to be 22.1 6.5
ng/106 cells/24 hours including inactive and active ones, but
96% of TGF-/3 in the conditioned media was in inactive or latent
forms.
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Fig. 4. Time course of TPA -induced TGF-3 mRNA expression. Mesangial cells were serum-starved for 48 hours, and exposed to TPA (100 nM)
in MEM containing 0.5% FCS. At the indicated time point following stimulation with TPA, RNA was isolated from the cells and subjected to
Northern blot analysis [2 jig poly (A4 RNAJlane] using nick-translated TGF-J31 and J3-actin cDNA probes.
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Fig. 5. Measurement of TGF-f3 like activities in the conditioned medium by mesangial cells before and after activation of latent TGF-f3 using
CCL-64 cell growth-inhibition assay. A. CCL-64 cells plated in 24-well culture plates were incubated for 24 hours in MEM containing 1% FCS,
and then control or test samples were added and incubated for another 16 to 24 hours. Subsequently, [3H1-thymidine was pulsed for 3 to 5 hours
and [3H]-thymidine incorporation was measured. The result of a representative experiment is shown. Samples are: TGF-/3 at the indicated
concentration (solid line), CM with heat or acid activation (•), CM with heat or acid activation in the presence of anti-TGF-/3 neutralizing
antibodies (A). CM were added at the indicated dilutions. B. [3H]-thymidine incorporation in CCL-64 cells were measured as described above.
Samples are: CM with heat or acid activation (•), CM without heat or acid activation (0), CM without heat or acid activation in the presence of
anti-TGF-/3 neutralizing antibodies (s).
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Immunoblot analysis for TGF-13 protein 12.5 kDa protein, the size compatible with that of a subunit of
To confirm the existence of TGF-f3 protein in CM, we further mature TGF-/31 peptides (Fig. 6). Together with the results of
performed immunoblot analysis. The results revealed single bioassay shown above, it is indicated that cultured mesangial
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Fig. 6. immunoblot analysis of TGF-fi secreted by mesangial cells.
Serum-free MEM conditioned by mesangial cells for 24 to 48 hours was
dialyzed against I msi acetic acid, lyophilized, and subjected to
SDS-polyacrylamide gel electrophoresis and transfer to a polyvinyli-
dene difluoride filter followed by immunoblot analysis using specific
polyclonal anti-TGF-/3l antibodies as described in the Methods section.
Left (negative control), serum-free MEM without conditioning; Middle
(TGF-13), TGF-/3 proteins (100 ng) as positive control; Right (condi-
tioned media), serum-free MEM conditioned by mesangial cells for 24
to 48 hours.
cells secrete biologically active TGF-/3 proteins but mostly in
inactive or latent forms.
Inhibition of[3H]-thymidine incorporation in mesangial cells
by TGF-f3 and stimulation by anti-TGF-/3 neutralizing
antibodies
TGF-p has been shown to modulate mesangial cell growth [9,
101. Our results showed that exogenously added TGF-/3 dose-
dependently inhibited [3H]-thymidine incorporation in mesan-
gial cells (Fig. 7). The effect of TGF-/3 was seen at concentra-
tions higher than 10 p, reaching the maximum at 40 p. To
determine whether the growth of cultured mesangial cells 'were
under influence of TGF-13 endogenously secreted by mesangial
cells into the media, we next examined the effect of anti-TGF-/3
neutralizing antibodies on mesangial cell growth. As shown in
Figure 8, addition of anti-TGF-/3 neutralizing antibodies signif-
icantly augmented [3H]-thymidine incorporation in mesangial
cells incubated both in the MEM containing 10% FCS and
serum-free MEM with or without TPA, whereas control non-
immune IgG had no effect. The growth-stimulatory effect of
anti-TGF- neutralizing antibodies in mesangial cells incubated
in serum-free MEM was significantly greater when TPA was
added to the medium (42% increase with anti-TGF-f3 neutraliz-
ing antibodies in the presence of TPA vs. 16% increase in the
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Fig. 7. Effect of TGF-f3 on [3H]-thymidine incorporation in mesangial
cells. Mesangial cells plated in 24-well plates were serum-starved for
two days in MEM containing 0.5% FCS, and subsequently the medium
was changed to MEM containing 10% FCS with the addition of various
concentrations of TGF-13, and incubated for two days. [3H]-thymidine
incorporation in mesangial cells during the last six hours was measured.
Bars are mean SD of triplicate determinations from a representative
experiment. Similar results were obtained in three additional experi-
ments. * Significantly different (P < 0.05, by Student's 1-test) from the
control value in MEM containing 10% FCS in the absence of TGF-/3.
Table 1. Effect of TGF-/3 and anti-TGF-13 neutralizing antibodies on
mesangial cell number
Samples
Incubation time
3 days 7 days
Control 6220 1750 30830 1410
TGF-l3 M
10 4970 410 24170 1730
40 3770 1350 16440 4O90
100 3050 640 13000
Anti-TGF-13 neutralizing 9970 95Ø 42000 4300
antibodies
Values are mean SD of triplicate determinations from a represen-
tative experiment. Similar results were obtained in two additional
experiments.
a P< 0.05, b<0.005, significantly different from control by Student's
1-test
absence of TPA, P < 0.05 by Student's paired t-test) (Figure.
8B).
Cell number analysis
To confirm the effects of TGF-f3 and anti-TGF-f3 neutralizing
antibodies on the mesangial cell proliferation, we performed the
cell number analysis. As shown in Table 1, significant reduction
of cell number was observed as compared to control values
three days after addition of TGF-/3 at 100 p, and at 10 M or
higher seven days later. Moreover, a proliferative effect was
seen at three or seven days after addition of anti-TGF-f3
neutralizing antibodies. These results were almost consistent
with the [3H]-thymidine incorporation data shown above.
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Fig. 8. Effect of anti-TGF-/3 neutralizing antibodies on [3H]-rhymidine incorporation in mesangial cells. A. Mesangial cells were incubated in
MEM containing 10% FCS in the absence or the presence of anti-TGF-/3 neutralizing antibodies (20 g/ml) or non-immune rabbit IgG (20 fLglml),
and [3H]-thymidine incorporation in mesangial cells for 48 hours was measured. Bars are the mean SEM of the results from four separate
experiments performed in triplicate. * Significantly different (P < 0.05, by Student's t-test) from control. B. Mesangial cells were incubated for 48
hours in serum-free MEM with or without 100 nri TPA in the absence or the presence of anti-TGF-/3 neutralizing antibodies (20 g/ml).
[3H1-thymidine incorporation in mesangial cells during the 48 hours was measured. Bars are the mean SEM of the results from six separate
experiments performed in triplicate. * Significantly different (P < 0.05, by Student's f-test) from control, ** Significantly different (P < 0.05) from
the value in the presence of TPA without anti-TGF-l3 neutralizing antibodies.
Based on these results it is suggested that TGF-f3 secreted by
mesangial cells indeed exerts a growth-inhibitory action on
mesangial cells themselves in culture.
Discussion
It has been recently reported that in experimental glomeru-
lonephritis the expression of TGF-/3 was augmented in parallel
to the mesangial matrix accumulation [14], which could be
inhibited by anti-TGF-$ neutralizing antibodies. These obser-
vations suggest a crucial role for TGF-p in the pathogenesis of
glomerulonephritis, although what cell types in the glomerulus
were responsible for the production of TGF-/3 and the mecha-
nism by which the TGF-/3 mRNA expression was stimulated
remain to be defined [15].
Here we first demonstrated that cultured rat glomerular
mesangial cells express TGF-f3 mRNA, and synthesize and
release into the culture media a polypeptide that shares immu-
nological and biological features consistent with TGF-f3. Bioas-
say for TGF-/3 using CCL-64 cells is a reliable and well
established method to quantify TGF-f3 [15, 25, 26—281. The
observation that the CCL-64 cell growth-inhibitory effects of
the conditioned media were totally recovered by anti-TGF-/3
neutralizing antibodies at all data points clearly showed the
activities we measured were TGF-/3 specific (Fig. 5). Moreover,
immunoblot analysis using specific polyclonal anti-TGF-/3 anti-
bodies directly demonstrated the presence of TGF-/3 proteins in
the conditioned media (Fig. 6).
Our study showed that the amounts of TGF-/3 produced by
mesangial cells were estimated to be 22.1 6.5 ng/106 cells/24
hours and the concentrations were 150 450 M (282.5 119.3
pM), but 96% of TGF-13 in the conditioned media was in inactive
forms. The amounts of TGF-13 production were nearly compa-
rable or larger than those reported in other cell types [26, 29],
suggesting a potential role of mesangial cells as a source of
TGF-/3 in the glomerulus. We demonstrated that mesangial cells
also expressed TGF-f3 binding protein mRNA (data not shown),
suggesting that TGF-f3 is secreted by mesangial cells as an
inactive form probably bound to TGF-13 binding protein. By our
bioassay study about 4% of TGF-/3 in the conditioned media
was in active or mature forms. The existence of biologically
active TGF-f3 in the conditioned media was further supported
by the observation that addition of anti-TGF-13 neutralizing
antibodies significantly increased [3H]-thymidine incorporation
in mesangiaf cells (Fig. 8). Although TGF-/3 may be activated
from its precursor by heat or acid activation in vitro, the
mechanism of the activation in vivo or in our culture conditions
remains to be elucidated. It is possible that some proteases such
as plasmin generated by mesangial cells or inflammatory cells
might be involved in the activation of TGF-f3 in vivo [1, 23].
Next we investigated whether there are any factor(s) which
could modulate TGF-J3 mRNA expression by mesangial cells. It
has been reported that TGF-/3 mRNA expression is stimulated
by TPA in NIH3T3 cells [301, by EGF or PDGF in normal rat
kidney fibroblasts [311, and by TGF-f3 itself in rat osteosarcoma
cells [31]. Our results demonstrated that removal of FCS for
two days decreased the TGF-/3 mRNA level, which was then
stimulated by re-addition of 17% FCS reaching the maximum at
nine hours (Figs. 1, 2). TPA also stimulated TGF-f3 mRNA
levels of mesangial cells reaching the maximum at six or nine
hours (Fig. 4). PDGF, TGF-p, or EGF (data not shown) had no
effect. Induction of TGF-p mRNA by TPA is compatible with
the report which demonstrated the presence of TPA responsive
element at the 5' region of the TGF-/3 gene [32], and suggests
that the TGF-/3 mRNA expression was mediated, at least in
1326 Kaname et a!: TGF-13 secretion in mesangial cells
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